<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363411</url>
  </required_header>
  <id_info>
    <org_study_id>RUNtoBBV-001</org_study_id>
    <nct_id>NCT04363411</nct_id>
  </id_info>
  <brief_title>Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections</brief_title>
  <acronym>RUNtoBBV</acronym>
  <official_title>Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title Reaching out to the UNdiagnosed people infected with blood-borne viral infections
      (RUNtoBBV) Objectives 1. To study the efficacy of an outreach methodology to increase the
      uptake for screening, linkage to care and treatment in (active or former) people who use
      drugs (PWUD) Trial design Prospective multicenter interventional cohort design Number of
      subjects 336 inclusions (with prevalence of HCV Ab: 30%)

        -  168 Antwerp

        -  168 Limburg

      Selection criteria Inclusion criteria:

        -  18 years of age

        -  History of/ or active drug use

        -  Written informed consent obtained Exclusion criteria

        -  Currently enrolled in centralized OST program of Free Clinic or CAD Limburg Endpoints
           The following endpoints will be compared between the centers in Limburg and Antwerp:
           (Main outcome in bold)

      Main objectives:

        -  Prevalence of blood-borne viral infections in Belgian (former or active) PWUD:

             -  HCV infection (number of HCV Ab+ / number of screened PWUD)

             -  HBV infection (number of HBsAg+/number of screened PWUD)

             -  HIV infection (number of HIV Ab+/number of screened PWUD)

        -  Analysis of linkage to care to hepatologist/ infectiologist (number of patients who
           adhered to their consultation/number of referred patients)

      Secondary objectives:

        -  Analysis of risk behavior/sociodemographics linked to presence of BBV infections

        -  Analysis of uptake of anti(retro)viral treatment (number of patients started on
           treatment/number of patients needing treatment)

        -  Analysis of treatment adherence (adherence to treatment consultations/total planned
           consultations)

        -  Analysis of treatment outcome (total number of cured or virally suppressed
           patients/total number of treated patients)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Actual">October 22, 2019</completion_date>
  <primary_completion_date type="Actual">October 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV Ab+ (Hepatitis C Virus antibody)</measure>
    <time_frame>day 1</time_frame>
    <description>test using whole capillary blood (finger prick testing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HBsAg+ (Hepatitis B surface Antigen)</measure>
    <time_frame>day 1</time_frame>
    <description>test using whole capillary blood (finger prick testing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV Ab+ (human immunodeficiency virus) antibody</measure>
    <time_frame>day 1</time_frame>
    <description>test using whole capillary blood (finger prick testing)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>4. Questionnaire to Identify risk factors associated with the aforementioned blood borne viral infections (hepatitis C, hepatitis B and HIV)</measure>
    <time_frame>day 1</time_frame>
    <description>i. Combine results from positive finger prick test with questionnaire regarding sociodemographic factors, migration, risk factors for blood born viruses (sexual contacts, incarceration, drug use). The questionaire does not include a score on scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of uptake of anti(retro)viral treatment</measure>
    <time_frame>Day 1</time_frame>
    <description>percentage of HCV positive clients who started treatment in relation of total of HCV positive clients needing treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of treatment adherence</measure>
    <time_frame>up to one year</time_frame>
    <description>percentage of patients reaching end-of treatment response, who present at the consultation, in relation to total patients in treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of treatment outcome</measure>
    <time_frame>month 18</time_frame>
    <description>total number of cured or virally suppressed patients/total number of treated patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">425</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis c</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>drug use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>finger prick screening for BBV infections and questionnaires by outreaching methodology</intervention_name>
    <description>Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities.</description>
    <arm_group_label>drug use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  History of drug use

          -  Active drug use

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Currently enrolled in OST program of Free Clinic or CAD Limburg (centralized OST
             provision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Robaeys, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rob Bielen, dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Free Clinic Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Free Clinic Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAD Limburg</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Maas en Kempen</name>
      <address>
        <city>Maaseik</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mariaziekenhuis Noord-limburg</name>
      <address>
        <city>Overpelt</city>
        <zip>3900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Trudo</name>
      <address>
        <city>Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Vesalius</name>
      <address>
        <city>Tongeren</city>
        <zip>3700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Geert Robaeys</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

